Atara Biotherapeutics, Inc. (26)

Browse by Contract Category

Contracts

Form of Pre-Funded Warrant (Filed With SEC on December 9, 2020)
First Amendment to Lease, by and between BXP 611 Gateway Center LP and Atara Biotherapeutics, Inc., dated as of October 21, 2020 (Filed With SEC on November 9, 2020)
Amended and Restated 2018 Inducement Plan (Filed With SEC on November 9, 2020)
Third Amended and Restated Research and Development Collaboration Agreement, by and between Atara Biotherapeutics, Inc. and the Counsel of the Queensland Institute of Medical... (Filed With SEC on November 9, 2020)
Third Amended and Restated Exclusive License Agreement, by and between Atara Biotherapeutics, Inc. and the Counsel of the Queensland Institute of Medical Research, dated August... (Filed With SEC on November 9, 2020)
Form of Restricted Stock Unit Agreement and Restricted Stock Unit Grant Notice under the Amended and Restated 2014 Equity Incentive Plan (Filed With SEC on November 7, 2019)
Underwriting Agreement, dated as of December 8, 2020, by and among Atara Biotherapeutics, Inc., Citigroup Global Markets Inc., Evercore Group L.L.C. and Mizuho Securities USA LLC (Filed With SEC on December 9, 2020)
Form of Pre-Funded Warrant (Filed With SEC on May 28, 2020)
Underwriting Agreement, dated as of May 26, 2020, by and among Atara Biotherapeutics, Inc., Citigroup Global Markets Inc., Cowen and Company, LLC and Evercore Group L.L.C (Filed With SEC on May 28, 2020)
Description of Securities (Filed With SEC on February 27, 2020)
Commercial Manufacturing Services Agreement, by and between Atara Biotherapeutics, Inc. and Cognate BioServices, Inc., dated December 24, 2019 (Filed With SEC on February 27, 2020)
Amendment No. 5 to the Development and Manufacturing Services Agreement, by and between Atara Biotherapeutics, Inc. and Cognate BioServices, Inc., dated November 27, 2019 (Filed With SEC on February 27, 2020)
Amendment No. 4 to the Development and Manufacturing Services Agreement, by and between Atara Biotherapeutics, Inc. and Cognate BioServices, Inc., dated November 4, 2019 (Filed With SEC on February 27, 2020)
Sales Agreement, dated February 27, 2020, by and between Atara Biotherapeutics, Inc. and Cowen and Company, LLC (Filed With SEC on February 27, 2020)
Amendment No. 3 to the Development and Manufacturing Services Agreement, by and between Atara Biotherapeutics, Inc. and Cognate BioServices, Inc., dated June 28, 2019 (Filed With SEC on November 7, 2019)
Amended and Restated Amendment No. 2 to the Development and Manufacturing Services Agreement, by and between Atara Biotherapeutics, Inc. and Cognate BioServices, Inc., dated... (Filed With SEC on November 7, 2019)
Second Amended and Restated Exclusive License Agreement, by and between Atara Biotherapeutics, Inc. and the Counsel of the Queensland Institute of Medical Research, dated August... (Filed With SEC on November 7, 2019)
Second Amended and Restated Research and Development Collaboration Agreement, by and between Atara Biotherapeutics, Inc. and the Counsel of the Queensland Institute of Medical... (Filed With SEC on November 7, 2019)
Form of Restricted Stock Unit Agreement and Restricted Stock Unit Grant Notice under the 2018 Inducement Plan (Filed With SEC on November 7, 2019)
Form of Executive Employment Agreement (Filed With SEC on August 8, 2019)
Form of Pre-Funded Warrant (Filed With SEC on July 22, 2019)
Underwriting Agreement, dated as of July 18, 2019, by and among Atara Biotherapeutics, Inc., Citigroup Global Markets Inc., Goldman Sachs & Co. LLC and Cowen and Company, LLC (Filed With SEC on July 22, 2019)
Executive Employment Agreement, dated May 23, 2019, by and between Pascal Touchon and Atara Biotherapeutics, Inc (Filed With SEC on May 28, 2019)
Amendment No. 1 to the Exclusive License Agreement, by and between Atara Biotherapeutics, Inc. and Memorial Sloan Kettering Cancer Center, dated as of August 30, 2018 (Filed With SEC on February 26, 2019)
Sales Agreement, dated February 26, 2019, by and between Atara Biotherapeutics, Inc. and Cowen and Company, LLC (Filed With SEC on February 26, 2019)
Transition and Separation Agreement, dated January 2, 2019, by and between Isaac Ciechanover and Atara Biotherapeutics, Inc (Filed With SEC on January 3, 2019)